Merck’s first quarter results drew a positive market reaction, reflecting operational resilience despite a 1.6% ...

The approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...

Shareholders of Merck would probably like to forget the past six months even happened. The stock dropped 20.3% and now trades ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has ...

Merck (NYSE:MRK) recently initiated the IDeate-Prostate01 phase 3 trial, dosing the first patient for its investigational drug ifinatamab deruxtecan, aimed at treating metastatic castration-resistant ...

Alvotech and Dr. Reddy’s have entered into a collaboration and license agreement to co-develop, manufacture and commercialize ...

Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

The shipments have vaulted Ireland, a country of only five million people, into the second-largest goods-trade imbalance with the U.S., trailing only China.

Pfizer PFE is one of the largest and most successful drugmakers in oncology. It boasts a strong portfolio of approved cancer ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...